AZN.L: Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

UK Markets open in 2 hrs 51 mins

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
4,255.50-63.00 (-1.46%)
At close: 5:11PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close4,318.50
Open4,298.00
Bid4,240.00 x 6100
Ask4,420.00 x 13000
Day's range4,245.50 - 4,386.72
52-week range3,680.00 - 5,505.00
Volume5,267,069
Avg. volume2,971,033
Market cap53.84B
Beta0.46
PE ratio (TTM)21.83
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield2.80 (5.37%)
Ex-dividend dateN/A
1y target estN/A
  • AstraZeneca Plc breached its 50 day moving average in a Bearish Manner : AZN-GB : January 23, 2017
    Capital Cube20 hours ago

    AstraZeneca Plc breached its 50 day moving average in a Bearish Manner : AZN-GB : January 23, 2017

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AstraZeneca Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Reuters3 days ago

    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

    Bristol-Myers Squibb Co (BMY.N) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (MRK.N) leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.

  • Reuters - UK Focus3 days ago

    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

    Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck (Jakarta: 28586808.JK - news) & Co Inc's leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck (LSE: 0O14.L - news) shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.